The Latin America gene expression market size was estimated at USD 374.9 million in 2019 and is expected to expand at a compound annual growth rate (CAGR) of 5.6% from 2020 to 2027. Gene expression analysis is expected to witness increased adoption owing to its potential applications in screening gene-based disorders.
Realizing the high potential of genomic studies, researchers are being encouraged to conduct these studies. Since the completion of the Human Genome Project, investment has been high in genomic research. Furthermore, programs such as Precision Medicine Initiative and advances in companion diagnostic studies are anticipated to accelerate the adoption of expression analysis. The promising results of these studies reflect the potential to improve healthcare facilities through genomics.
Rapid advances in high-throughput technologies such as RNA-Sequencing, variants of PCR, and data analysis and interpretation algorithms have provided researchers with highly efficient tools to conduct expression analysis. Limitations in the usage of existing technologies along with the expanding scope of application for gene expression analysis have accelerated the development of novel approaches.
For instance, microarray has limitations due to predesigned oligonucleotide probes and hybridization-based detection. This limits its use in the development of new drugs. However, to overcome this, a new technique that integrated Cap Analysis of Gene Expression (CAGE) with single-molecule sequencing technique has been developed. CAGE allows comprehensive mapping of human transcription start sites and their promoters. It also allows the quantification of mRNA sets in the cell.
Gene expression analysis is estimated to witness rapid adoption in oncology research to understand the mechanism and progression of cancer. Various companies are involved in the development of kits for accurate and easy diagnosis of cancer through profiling gene expression. Thus, a rise in cancer incidence is anticipated to be one of the key factors anticipated to drive the market.
According to October 2019 study, Cuba had the highest cancer rate, with the disease affecting 136.9 men and 90.4 women per 100,000 population. While Mexico had the lowest rate of cancer with 63.8 men per 100,000 population and 61.9 women per 100,000 population. Common types of cancer observed in this region are stomach cancer, colorectal cancer, lung cancer, and breast cancer.
cDNA synthesis and conversion segment dominated the market and accounted for the largest revenue share of 27.5% in 2019. The segment generated the largest revenue of USD 103.4 million in 2019. Rapid advances in sequencing technologies along with its rising demand for precision medicine has accelerated the development of cDNA synthesis for creating genomic libraries. A broad range of kits are available for cDNA synthesis to suit the need depending on the sample size, the number of reactions, and optimal reaction temperature
Besides, reverse transcription of cloned or recombinant RNAs is developed to study gene expression for recombinant genetic engineering. The number of novel cDNA synthesis and library preparation kits launch has increased with rising demand for NSG including RNA-Seq techniques in gene expression analysis. The declining cost of NGS is expected to increase the adoption of gene expression analysis. cDNA library preparation being a crucial step in the process, it is projected to witness lucrative growth.
PCR analysis also makes a significant contribution to the industry. PCR analysis allows the development of assays for most clinical matrices, for almost any target gene. Assays for various endogenous control genes can be developed using specific probe sets and primers. Thus, a projected rise in the adoption of clinical programs is expected to boost segment growth.
In Brazil, the Department of Biology, Federal University of Vicosa, and the School of Veterinary Medicine, Ceara State University are conducting gene expression studies using the real-time PCR method. Such research programs are expected to drive the adoption of these techniques in the Latin American market. Furthermore, companies such as Agilent and QIAGEN provide PCR-related products through their subsidiaries and distribution partners. Thus, such companies are expected to boost revenue generation in the region.
Considering the improvements in technology and investments to develop better data analytics platforms, it is expected that data analysis and interpretation would witness rapid growth. Challenges in data analysis and interpretation of the expression results have accelerated R&D for better platforms and algorithms for data analytics.
The kits and reagents segment dominated the market with a revenue share of 75.9% in 2019. Kits and reagents form an essential part of any genomic study. The industry offers a broad range of products to meet the specific needs right from sample collection to data interpretation. The ongoing release of novel kits has made gene expression more appealing to researchers as well as clinicians.
Furthermore, the expansion of emerging players, such as 10x Genomics that has a robust portfolio of gene expression kits and reagents, in the region is anticipated to positively influence the revenue growth in the segment. Moreover, ESALQ Genomics Center in Brazil uses the TruSeq RNA Sample Preparation Kit manufactured by Illumina, Inc. for gene expression studies. Such companies are anticipated to boost revenue generation by increasing product availability in the market.
DNA chips are anticipated to witness the fastest growth in the coming years owing to its rising adoption in gene expression analysis. These products enable high throughput analysis of gene expression of large mammalian genomes. With advances in technology, DNA chips find fresh applications in various fields of biotechnology such as biomedicine, drug discovery, diagnostics, and many others.
High-Plex dominated the Latin America gene expression market and occupied the largest revenue share of 62.6% in 2019. With a sample size of more than 1,000 targets, a high plex technique of gene expression analysis is used. These include microarrays and sequencing. Rapid adoption for gene expression analysis in various genomic studies is attributed to the substantial market share of this segment. The presence of market participants such as Thermo Fisher Scientific that are engaged in providing fast and high-throughput solutions for multiplexed gene expression quantitation is expected to enhance the potential of this segment.
Furthermore, novel workflow providing high-plex gene expression analysis that reduces hands-on time in comparison to conventional techniques such as qPCR are introduced. Eliminating the need for upfront probe validation makes the technique simpler and increases accuracy. Multiplexed digital characterization systems with spatially resolved solutions are also developed. Increased adoption of gene expression profiling in various applications such as identification of biomarkers for potential combination therapy is expected to drive segment growth.
With increased accuracy, high-plex capacity techniques are expected to witness lucrative growth in the region. In February 2020, NanoString Technologies, Inc. announced 10 studies using GeoMx Digital Spatial Profiler (DSP)-a high multi-plex RNA product. These studies are focused on the discovery of novel biomarkers. The company offers products in Latin American countries through its distributors, which is anticipated to positively enhance the adoption of this technique further propelling the segment growth.
Drug discovery and development generated the largest revenue share of 42.5% in 2019. Adoption of gene expression in the process of drug discovery from the early phases of discovery to the later phases of clinical development is expected to result in substantial growth in this segment in the coming years. Gene expression is applicable in depicting the drug action at the molecular level.
Moreover, whole-genome expression profiling provides glimpses of the cellular transcriptional patterns to disclose the temporal cellular responses following exposure to a drug candidate. The combination of next-generation DNA sequencing and genome-wide expression analysis allows a detailed delineation as well as dissection of the cell-based responses at a molecular level. Thus, increased adoption of screening of gene expression libraries for fast-track drug development is projected to increase the revenue generation for the segment.
The increasing interest of pharmaceutical companies in investing in gene expression analysis is anticipated to have a positive impact on the application of gene expression technologies in the drug discovery and development segment. The pharmaceutical industry in Latin America is expected to witness considerable growth in the coming years. Global pharmaceutical companies operating in Latin America are investing in new techniques for drug development. This is anticipated to further boost the segment growth.
RNA expression generated the largest revenue share of 43.3% in 2019. This is owing to the higher adoption of the technique. RT-PCR is poised to witness rapid growth over the forecast period. The technique is considered a gold standard for the detection and measurement of gene expression for its accuracy and sensitivity. It is one of the simplest techniques for gene expression analysis.
PCR techniques are preferred over others for smaller sample size and low-expression genes as it offers higher accuracy results. RT-PCR has revolutionized gene expression studies by accelerating the speed and efficiency of results obtained. Furthermore, its enhanced variants such as qPCR, digital PCR, and RT-PCR are applicable in comparative or differential expression analysis.
Being a well-established technique, various research institutes in Latin American countries are using this technique in gene expression studies. For instance, researchers from Nucleo de Biotecnologia de Sobral; Universidade Federal do Ceara used real-time PCR to quantify mRNA expression in tissues.
In addition, Plant Genomics and Breeding Center, Brazil, Embrapa Uva e Vinho, Bento Gonçalves, Brazil, and Universidade Federal do Rio de Janeiro used the RT-qPCR technique in the selection and testing of Reference Genes. Thus, an increasing number of research institutes using the PCR technique is anticipated to boost the revenue generation in this segment by increasing application in the region.
Brazil dominated the market and accounted for the largest revenue share of 17.4% in 2019 owing to economic growth in the country. Brazil has strategic collaborations with other nations, with initiatives such as the Canada-Brazil Joint Committee for Cooperation on Science, Technology, and Innovation. The joint committee for science, technology, and innovation is expected to bring together leading public and private sector experts to form innovative strategies for life sciences and other industrial fields.
Colombia's gene expression market is driven by continuous efforts undertaken by international sequencing and gene expression companies. For instance, in October 2019, the subsidiary of Veritas Genetics, Veritas Intercontinental, inaugurated an office in Bogota, Columbia to manage the operations and commercial activity for the company in Columbia and Latin America. This expanded the sequencing and preventive medicine landscape, finally boosting the revenue generation in this region.
The presence of several distributors and suppliers of key companies operating in the market further fosters revenue generation. AnnarDiagnóstica Import S.A.S. is a distributor of Illumina in Columbia. GENTECH, QUIMIOLAB Ltda, and Biodiagnostica are distributors of QIAGEN operating in this region, whereas GenProducts Company is the distributor of Quantabio.
The presence of key market players offering products required for Northern blotting is anticipated to positively impact the market. Thermo Fisher Scientific offers a wide range of products for RNA isolation. In addition, Pall Corporation provides products required for northern blotting.
These companies operate in the countries of Latin America through their offices and distributors. Moreover, Qiagen is present in the market through its subsidiaries and commercial partners. For instance, MEDICAL INSIGHT SAC is Qiagen’s commercial partner in Peru. Such companies are expected to witness considerable growth in the coming years owing to an increase in sales of these products. Some of the prominent companies in the Latin America gene expression market include:
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc
Thermo Fisher Scientific, Inc
Bio-Rad Laboratories, Inc
Novogene Co., Ltd
ONKOS Diagnósticos Moleculares LTDA
Market size value in 2020
USD 396.4 million
Revenue forecast in 2027
USD 578.3 million
CAGR of 5.6% from 2020 to 2027
Base year for estimation
2016 - 2018
2020 - 2027
Revenue in USD million and CAGR from 2020 to 2027
Revenue forecast, competitive landscape, growth factors and trends
Process, product, capacity, application, technique, region
Brazil; Mexico; Argentina; Chile; Colombia; Peru; Ecuador; Dominican Republic; Guatemala; Cuba; Panama; Venezuela; Costa Rica; Uruguay
Key companies profiled
Illumina, Inc.; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Novogene Co., Ltd.; Danaher; Sysmex Corporation; Idengene SA; ONKOS Diagnósticos Moleculares LTDA
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the Latin America gene expression market on the basis of process, product, capacity, application, technique, and region:
Process Outlook (Revenue, USD Million, 2016 - 2027)
cDNA Synthesis & Conversion
Data Analysis & Interpretation
Product Outlook (Revenue, USD Million, 2016 - 2027)
Kits & Reagents
Capacity Outlook (Revenue, USD Million, 2016 - 2027)
Low- to Mid-Plex
Application Outlook (Revenue, USD Million, 2016 - 2027)
Drug Discovery & Development
Biotech & Microbiology
Technique Outlook (Revenue, USD Million, 2016 - 2027)
In vitro Transcription/Nuclear Run-On Assays
Gel Shift Assays
Chromatin Immunoprecipitation (ChIP)
Protein Expression & Posttranslational Modification Analysis
2-D Gel Electrophoresis
Regional Outlook (Revenue, USD Million, 2016 - 2027)
Dominican Republic (República Dominicana)
b. The Latin America gene expression market size was estimated at USD 0.37 billion in 2019 and is expected to reach USD 0.40 billion in 2020.
b. The Latin America gene expression market is expected to grow at a compound annual growth rate of 5.57% from 2020 to 2027 to reach USD 0.58 billion by 2027.
b. cDNA synthesis & conversion generated the largest revenue of USD 103.44 million in 2019. Rapid advances in sequencing technologies along with its rising demand for precision medicine has accelerated the development of cDNA synthesis for creating genomic libraries.
b. Some key players operating in the Latin America gene expression market include Illumina, Inc.; F. Hoffmann-La Roche Ltd; Agilent Technologies, Inc; Thermo Fisher Scientific, Inc; Bio-Rad Laboratories, Inc; Novogene Co., Ltd; Danaher; Sysmex Corporation; Idengene SA; and ONKOS DiagnÃ³sticos Moleculares LTDA.
b. Key factors that are driving the Latin America gene expression market growth include the declining price of sequencing, technological advancements in gene expression analysis, rising investment in genomic research, an increase in cancer incidence, and increased focus on precision medicine.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."